35066-32-1

Usage

Uses

Used in Flavoring Industry:
Methyl 3-cyano-4-Methylbenzoate is used as a flavoring agent in the food and beverage industry, providing a sweet, fruity aroma to various products.
Used in Pharmaceutical Synthesis:
Methyl 3-cyano-4-Methylbenzoate is used as an intermediate in the synthesis of pharmaceuticals, contributing to the development of new drugs and medications.
Used in Agrochemical Synthesis:
Methyl 3-cyano-4-Methylbenzoate is also utilized in the synthesis of agrochemicals, playing a role in the production of various agricultural chemicals and pesticides.
Used in Organic Synthesis:
Methyl 3-cyano-4-Methylbenzoate serves as an intermediate in organic synthesis, enabling the production of a wide range of other chemicals and compounds.
Used in Chemical Production:
As an intermediate in the production of various chemicals, Methyl 3-cyano-4-Methylbenzoate contributes to the manufacturing process of different chemical products across various industries.

InChI:InChI=1/C10H9NO2/c1-7-3-4-8(10(12)13-2)5-9(7)6-11/h3-5H,1-2H3

Upstream product

• 186581-53-3 diazomethane 
• 2458-12-0 3-amino-p-toluic acid 
• 151-50-8 potassium cyanide 
• 1943-88-0 2,4-dicyanotoluene 
• 96-98-0 4-methyl-3-nitrobenzoic acid 
• 104901-43-1 methyl 3-bromo-4-methylbenzoate 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 19158-51-1 P-toluenesulfonyl cyanide 
• 18595-18-1 3-amino-4-methyl benzoic acid methyl ester 
• 557-21-1 zinc(II) cyanide 
• 7697-26-9 3-bromo-4-methylbenzoic acid 
• 90347-66-3 methyl 3-iodo-4-methylbenzoate 

Downstream Products

• 219519-17-2 4-bromomethyl-3-cyanobenzoic acid methyl ester 
• 23038-61-1 dimethyl 4-methylbenzene-1,3-dicarboxylate 

Relevant academic research and scientific papers

Enhanced accuracy of single-molecule diffusion measurements with a photocleavable energy-transfer dyad

A photocleavable energy-transfer dyad was synthesized, characterized, and applied to single-molecule fluorescence microscopy. After photocleavage, a combination of independent two-color single-molecule tracking and analysis of single-molecule energy-transfer efficiencies allows the determination of the temporal evolution of the relative distances between both fragments from the nm to the μm scale. This gives access to a broad range of diffusion coefficients. Copyright

BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS

The present invention relates to a compounds of general formula (I) inhibiting DDR1 and DDR2, particularly the invention relates to compounds that are benzylamine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of DDRs, in particular fibrosis.

BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS

The present invention relates to biaryloxy derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channel is involved.　The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

PHTHALAZINE DERIVATIVES, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF

The present invention provides a compound of formula I, a cis-trans isomer, an enantiomer, a diastereoisomer, a racemate, a solvate, a hydrate, or a pharmaceutical acceptable salt and ester thereof, a preparation method for preparing the same, a pharmaceutical composition comprising the same and a use of the compound as an α5-GABAA receptor regulator, wherein T, Z, A and Y are as defined in the description.

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication

An early lead from the AMD070 program was optimized and a structure-activity relationship was developed for a novel series of heterocyclic containing compounds. Potent CXCR4 antagonists were identified based on anti-HIV-1 activity and Ca2+ flux

Antithrombotic agents

This application relates to a compound of formula (I), a pharmaceutically acceptable salt of the compound, or a prodrug thereof, as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its

Regioselective Hydrolysis of Aromatic Dinitriles Using a Whole Cell Catalyst

A series of aromatic dinitriles have been examined as substrates for an immobilised whole cell Rhodococcus sp. that catalyses the hydrolysis of nitriles to amides and/or carboxylic acids.The fluorinated aromatic dinitriles 48 and 49 were regioselectively hydrolysed to the corresponding cyano amides 48a and 49a whereas the non-fluorinated analogues 41-44 were converted to cyano acids but with poorer regioselectivity.